[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frontotemporal-lobar-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frontotemporal-lobar-degeneration":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,75,100,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100496255","cognitive-reserve-and-response-to-speech-language-intervention-in-bilingual-speakers-with-primary-progressive-aphasia-100496255",false,"NCT05741853","Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia","Cognitive Reserve and Linguistic Resilience in Bilingual Hispanics With Primary Progressive Aphasia","Inclusion Criteria:\n\n* Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011)\n* Bilingual in Spanish and Catalan or bilingual in Spanish and English\n* Different proficiency levels across languages are expected, any prior experience in both languages is acceptable\n* Intervention study: Score of 15 or higher on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of 10 or higher on the Mini-Mental State Examination\n\nExclusion Criteria:\n\n* Other central nervous system or medical diagnosis that can cause symptoms\n* Other psychiatric diagnosis that can cause symptoms\n* Significant, uncorrected visual or hearing impairment that would interfere with participation\n* Prominent initial non-speech-language impairments (cognitive, behavioral, motoric)\n* Intervention Study: Score of less than 15 on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of less than 10 on the Mini-Mental State Examination",true,"ALL","40 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.\n\nThe overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how \"strong\" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Primary Progressive Aphasia","Dementia","Dementia, Frontotemporal","Alzheimer Disease","Neurodegenerative Diseases","Frontotemporal Lobar Degeneration","Apraxia, Motor","Dysarthria","Communication Disorders","Language Disorders","Speech Disorders","Neurocognitive Disorders","Aphasia","Bilingual Aphasia",[42,43,44,27,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"Dementia, ADRD","Bilingualism","Multilingualism","Bilingual Primary Progressive Aphasia","Cognitive Reserve","Language Decline","Bilingual Language Decline","Speech-Language Therapy","Bilingual Speech-Language Therapy","Spanish speakers","Spanish-Catalan Bilinguals","Spanish-English Bilinguals","Hispanic","Catalán","Catalan","Spanish","Castellano","Speech Therapy","Latino","Cognition","RECRUITING","2026-06-08",{"date":65,"type":66},"2026-06-10","ACTUAL",{"date":68,"type":66},"2023-05-01",{"date":70,"type":21},"2027-11-30",{"name":72,"class":73},"Stephanie Grasso","OTHER",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100474330","phase-3-pet-imaging-tau-accumulation-in-ftld-and-atypical-alzheimers-using-18f-pi-2620-100474330","NCT05456503","PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620","Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand [18F]-PI-2620","Inclusion Criteria: participants must fulfill all of the criteria for one of the following groups.\n\n1\\. Group 1: cognitively and neurologically normal subjects (CN, n=25)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Cognitively and neurologically normal according to one of the following criteria:\n\n   i. Mini-Mental Status Exam (MMSE; Folstein et al., 1975) score \\> 27, OR ii. Montreal Cognitive Assessment (MoCA; Carson et al., 2017; Nasreddine et al., 2005) score \\> 25, OR iii. Global Clinical Dementia Rating of 0, OR iv. Evaluation by a trained clinician\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. No history of early-onset neurodegenerative disease in biological siblings or parents, based on the investigators' assessment of the participant's self-reported history.\n\n2\\. Group 2: non-amnestic Alzheimer's disease (naAD, n=15)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having a non-amnestic syndrome attributed to likely AD pathology, including but not limited to logopenic-variant primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), behavioral\u002Fdysexecutive AD (bvAD), corticobasal syndrome due to AD (CBS-AD), non-amnestic mild cognitive impairment (naMCI), or non-amnestic AD (naAD).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n3\\. Group 3: FTLD likely due to tau (FTLD-tau, n=25)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having a neurodegenerative syndrome likely due to tau , including but not limited to progressive supranuclear palsy (PSP), non-fluent agrammatic primary progressive aphasia (naPPA), corticobasal syndrome (CBS), or behavioral-variant frontotemporal dementia (bvFTD).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n4\\. Group 4: FTLD likely due to TDP-43 (FTLD-TDP, n=12)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having a dementia syndrome associated with likely TDP-43 pathology, including but not limited to amyotrophic lateral sclerosis with frontotemporal dementia (ALS-FTD) or semantic-variant primary progressive aphasia (svPPA).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n5. Group 5: having a known genetic mutation associated with FTLD-tau (genetic FTLD-tau, n=12)\n\n1\\. Male or female ≥ 18 years of age 2. Currently enrolled in UNICORN (IRB #842873) with a genetic test result indicating a mutation in the MAPT gene.\n\n3\\. Clinically diagnosed by a trained clinician as having an appropriate neurodegenerative condition OR confirmed as an asymptomatic mutation carrier.\n\n4\\. Not clinically depressed, according to one of the following criteria: i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician 5. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n6\\. Group 6: having a known genetic mutation associated with FTLD-TDP (genetic FTLD-TDP, n=3)\n\n1. Male or female ≥ 18 years of age\n2. Currently enrolled in UNICORN (IRB #842873) with a genetic test result indicating a mutation in the GRN gene or in open reading frame 72 of chromosome 9 (C9orf72).\n3. Clinically diagnosed by a trained clinician as having an appropriate neurodegenerative condition OR confirmed as an asymptomatic mutation carrier.\n4. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n5. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n7\\. Group 7: amnestic Alzheimer's disease (naAD, n=15)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having amnestic mild cognitive impairment (MCI) or amnestic Alzheimer's disease (aAD).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\nExclusion Criteria for all groups: Participants will be excluded from enrollment if they meet any of the following criteria.\n\n1. The participant has any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the participant's safety or successful participation in the study.\n2. The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI scan within \\\u003C 6 months prior to enrollment that is likely to interfere with analysis of the PET scan.\n3. The participant is unable to tolerate or have a contraindication to imaging procedures in the opinion of an investigator.\n4. Females who are pregnant or breast feeding at the time of the baseline PET\u002FCT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET\u002FCT.\n5. The participant has a history of significant past or ongoing alcohol abuse or substance abuse, or dependence based on medical record review or self-reported (may be excluded at the discretion of the investigator.)\n6. The participant is enrolled in a clinical trial for a disease-modifying treatment that targets the molecular pathology underlying their neurodegenerative disease.","18 Years",{"count":84,"type":21},72,[86],"PHASE3","The investigators will compare \\[18F\\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.",[32,30,89],"Cognitively Normal","2025-11-03",{"date":92,"type":66},"2025-11-04",{"date":94,"type":66},"2022-09-19",{"date":96,"type":21},"2028-08",{"name":98,"class":73},"University of Pennsylvania",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":99},"100553802","the-skin-as-a-window-to-the-central-nervous-system-in-frontotempolar-lombar-degeneration-100553802","NCT06490822","The Skin as a Window to the Central Nervous System in Frontotempolar Lombar Degeneration","PROTEINOSKIN","Inclusion Criteria (patients):\n\n* Adressed or followed at memory clinic or ALS expert center at Nantes university hospital.\n* Aged 50-75 years\n* Fulfilling current diagnosis criteria for one of the disorder: vcfFTD, non-Alzheimer PPA (semantic or non fluent), DCB or PSP,ALS\n* MMSE ≥ 18\n* Membership of social security scheme\n\nInclusion Criteria (healthy volunteers):\n\n* No history of neurological disease, diabetes, or alteration\u002Fdamage of peripheral nervous system\n* Aged 50-75 years Paired to at least one patient on age (less or more 5 years)\n* MOCA ≥ 26\n* Membership of social security scheme\n\nNon inclusion Criteria (Patients and healthy volunteers):\n\n* Concomitting conditions affecting the peripheral nervous system such as but not limited to diabetes, renal failure, thyroid disorder, vitamin B12 deficiency, acute and chronic inflammatory diseases HIV, syphilis\n* Know allergy to local anesthetic\n* Known coagulopathy\n* Pregnant women or breastfeeding women\n* Person under court protection sous sauvegarde de justice\n* Person under guardianship\n* Inability to sign an informed consent\n\nNon inclusion criteria (Patients) • Patient with neurological disease other than FTLD\n\nNon inclusion criteria (Healthy volunteers) :\n\n• Evidence of neurological disorder at the inclusion including but not limted to FTLD, Parkinson disease, Alzheimer disease, lewy body dementia, Huntington disease, systemic lupus erythematosus multiple sclerosis; learning disabilities, mental retardation, severe hypoxic brain injuries, brain trauma with permanent cognitive impairments.","50 Years","75 Years",{"count":110,"type":21},80,[24],"Frontotemporal lobar degeneration (FTLD) is a clinically heterogeneous syndrome, characterized by progressive decline in behaviour and\u002For language. From a pathological standpoint, like the great majority of neurodegenerative disorders, FTLD are proteinopathies, which are characterized by the presence of specific protein deposits in the Central Nervous System (CNS). Accordingly, the two main deposits observed in FTLD are either made of Tau or transactive response DNA binding protein 43 (TDP-43).\n\nIn pathological conditions such as FTLD, both proteins are aggregated and hyperphosphorylated.\n\nIt is now well established that the pathological process in some proteinopathies such as synucleinopathies (of which Parkinson's disease is the main representative) is not limited to the brain but also widespread throughout the peripheral autonomic networks, including the autonomic innervation of the skin. In this context, many independent studies have shown that the pathological process in PD could be detected using routine punch skin biopsies opening the way for the development of original histopathological markers of the disease.\n\nOur hypothesis is that such a scenario could also occur in FTLDs and that the detection of the pathological tau or TDP-43 protein in the skin could help in diagnosing FTLD. This is especially relevant as, despite the recent progress in genetics, neurobiology and neuroimaging, there are no available biomarkers for FTLD.",[32],[115,116,117,118],"FTLD","tau","TDP43","skin biopsy","2024-12-17",{"date":121,"type":66},"2024-12-20",{"date":119,"type":66},{"date":124,"type":21},"2027-07",{"name":126,"class":73},"Nantes University Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":139,"conditions":140,"keywords":155,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":99},"100561944","neurodegenerative-diseases-progression-markers-markers-ndd-100561944","NCT06596746","Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study","MARKERS-NDD","Inclusion Criteria:\n\n* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders\n\n  * Patients with diagnosis of Parkinson's Disease\n\n    * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank\n  * Diagnosis of Movement Disorder not related to Parkinson's Disease\n\n    * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;\n    * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;\n    * Diagnosis of Essential Tremor\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n* Patients affected by cognitive impairment (CI) and dementia\n\n  * Diagnosis of probable:\n\n    * Lewy Body Dementia\n    * Alzheimer's Disease\n    * Mild Cognitive Decline\n    * Subjective memory complaints\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n\nExclusion Criteria:\n\n* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.","10 Years",{"count":137,"type":21},600,"OBSERVATIONAL","MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.",[31,141,142,143,144,145,30,146,147,148,149,150,32,151,152,28,153,154],"Parkinson Disease","Synucleinopathies","Lewy Body Disease","Multiple System Atrophy","Tauopathies","Corticobasal Degeneration","Supranuclear Palsy, Progressive","Atypical Parkinsonism","TDP-43 Proteinopathies","Amyotrophic Lateral Sclerosis","Movement Disorders","Cognitive Impairment","Iron Overload","Neurodegeneration With Brain Iron Accumulation (NBIA)",[31,156,157,158,159,160,161,162,163,164,165,166,167,168,169],"Markers","Gait analysis","Wearable inertial sensors","IMU","Artificial intelligence","AI-Video gait analysis","Handwriting analysis","Voice-based artificial intelligence systems","imaging","multimodal analysis","electroencephalogram","cortical activity","gut microbiota","laboratory blood chemistry parameters","2024-09-11",{"date":172,"type":66},"2024-09-19",{"date":174,"type":21},"2024-09-09",{"date":176,"type":21},"2034-09-09",{"name":178,"class":179},"Casa di Cura San Raffaele Cassino","NETWORK"]